Business Description
ISIN : US45784P1012
Share Class Description:
PODD: Ordinary SharesTotal Employee Number:
5,400Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.56 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.67 | |||||
Debt-to-EBITDA | 1.61 | |||||
Interest Coverage | 9.36 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 5.67 | |||||
Beneish M-Score | -2.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 26.4 | |||||
3-Year EBITDA Growth Rate | 63.4 | |||||
3-Year EPS without NRI Growth Rate | 57.2 | |||||
3-Year Book Growth Rate | 46.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.11 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 16.21 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.17 | |||||
9-Day RSI | 46.19 | |||||
14-Day RSI | 45.6 | |||||
3-1 Month Momentum % | 6.88 | |||||
6-1 Month Momentum % | -30.81 | |||||
12-1 Month Momentum % | -49.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.48 | |||||
Quick Ratio | 1.83 | |||||
Cash Ratio | 0.72 | |||||
Days Inventory | 189.56 | |||||
Days Sales Outstanding | 60.45 | |||||
Days Payable | 40.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 8.17 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 71.08 | |||||
Operating Margin % | 16.9 | |||||
Net Margin % | 12.29 | |||||
EBITDA Margin % | 19.35 | |||||
FCF Margin % | 8.7 | |||||
OCF Margin % | 16.74 | |||||
ROE % | 26.48 | |||||
ROA % | 11.85 | |||||
ROIC % | 20.21 | |||||
3-Year ROIIC % | 43.67 | |||||
ROC (Joel Greenblatt) % | 40.3 | |||||
ROCE % | 22.54 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 27.83 | |||||
Forward PE Ratio | 23.05 | |||||
PE Ratio without NRI | 25.36 | |||||
Shiller PE Ratio | 93.63 | |||||
Price-to-Owner-Earnings | 30.99 | |||||
PEG Ratio | 0.67 | |||||
PS Ratio | 3.43 | |||||
PB Ratio | 7.26 | |||||
Price-to-Tangible-Book | 8.22 | |||||
Price-to-Free-Cash-Flow | 39.39 | |||||
Price-to-Operating-Cash-Flow | 20.48 | |||||
EV-to-EBIT | 19.73 | |||||
EV-to-Forward-EBIT | 32.41 | |||||
EV-to-EBITDA | 18.18 | |||||
EV-to-Forward-EBITDA | 24.05 | |||||
EV-to-Revenue | 3.52 | |||||
EV-to-Forward-Revenue | 3.22 | |||||
EV-to-FCF | 40.43 | |||||
Price-to-GF-Value | 0.38 | |||||
Price-to-Projected-FCF | 4.27 | |||||
Price-to-Median-PS-Value | 0.33 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.01 | |||||
Price-to-Graham-Number | 3.04 | |||||
| Price-to-Net-Current-Asset-Value | 97.3 | |||||
Earnings Yield (Greenblatt) % | 5.07 | |||||
FCF Yield % | 2.57 | |||||
Forward Rate of Return (Yacktman) % | 21.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PODD
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Insulet Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,053.5 | ||
| EPS (TTM) ($) | 5.35 | ||
| Beta | 1.5347 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.29 | ||
| Volatility % | 39.35 | ||
| 14-Day RSI | 45.6 | ||
| 14-Day ATR ($) | 7.347664 | ||
| 20-Day SMA ($) | 152.8065 | ||
| 12-1 Month Momentum % | -49.74 | ||
| 52-Week Range ($) | 126.4 - 354.88 | ||
| Shares Outstanding (Mil) | 69.35 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Insulet Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Insulet Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-18 08:00 | In 182 days | ||
| Annual report for 2026 | 2027-02-18 | In 181 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-18 | In 181 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 78 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 77 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:00 | 166.82 (+0.29%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 166.82 (+0.29%) | ||
| Guidance call for 2026 | 2026-06-08 10:00 | 153.22 (+2.67%) | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-03 14:00 | 142.43 (-2.21%) | ||
| General meeting for 2026 | 2026-05-20 08:00 | 154.61 (+0.90%) |
Insulet Corp Frequently Asked Questions
Guru Commentaries on NAS:PODD
Insulet is the market leader in insulin pumps and offers the only tubeless automated insulin delivery system on the market. The company continues to benefit from strong patient adoption, expanding penetration in the type 2 diabetes market and the advantages of its pharmacy-based distribution model. However, we exited the position as increasing competition in the insulin pump market has reduced visibility into the company’s medium-term growth and market share outlook. While we continue to view Insulet as a high-quality franchise, we believe the growing competitive landscape introduces greater uncertainty around the durability of the profit cycle and chose to redeploy capital into higher conviction opportunities.
Insulet Corporation is a leader in medical technology, primarily known for its Omnipod Insulin Management System. Despite facing manufacturing and legal challenges, the underlying business is performing exceptionally well, as evidenced by a Q1 2026 revenue of $761.7 million, up 33.9%, and management raising their full-year revenue guidance to 21% - 23% growth. Insulet is aggressively targeting the Type 2 basal-only market, where the simplicity of a 'patch' has much higher adoption potential. Their technology is adaptable for delivering non-insulin drugs, which positions them well in the growing trend of subcutaneous drug delivery.
Press Release
Articles on Insulet Corp
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
